Evidence map›Paper›PMID 28646994›Full record

ArticleKidney international2017

Reading the tree leaves-how to enrich clinical trials of diabetic kidney disease.

Helen C Looker, Robert G Nelson

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Helen C LookerPhoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA.
Robert G NelsonPhoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA. Electronic address: rnelson@nih.gov.

Funding

Epidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1M
Intramural NIH HHS ZIA DK069062
6 · The paper itself

Abstract

Most participants selected for clinical trials of renoprotective drugs do not reach approved endpoints; thus, large trials or prolonged follow-up are needed to achieve adequate statistical power. Yamanouchi et al. used a classification and regression trees analysis to enrich enrollment criterion for patients at the highest risk of reaching these outcomes. Their findings suggest a greater role for newly identified biomarkers of diabetic kidney disease in the selection of participants for clinical trials.

Indexed as

Diabetic NephropathiesReadingBiomarkersHumansBiomarkers

Identifiers

PMID28646994
PMCPMC6380356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.